EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Unanticipated Pathological Laughter Following Atomoxetine Administration in a Child With Autism Spectrum Disorder and Attention‐Deficit/Hyperactivity Disorder

Alireza Zibaee, Forouzan Elyasi iD, Arghavan Fariborzifar iD, Elham Shirazi

Neuropsychopharmacology Reports · 2025-09 · 45 (3)

DOI: 10.1002/npr2.70028 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 28.07.2025. Verfasst von Alireza Zibaee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Hauptthemen laut MEDLINE: Atomoxetine Hydrochloride, Autism Spectrum Disorder, Attention Deficit Disorder with Hyperactivity, Laughter. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atomoxetine, a selective norepinephrine reuptake inhibitor (NRI), is commonly prescribed for attention‐deficit/hyperactivity disorder (ADHD) and has shown effectiveness in children with autism spectrum disorder (ASD). Although mood disturbances and psychiatric symptoms are recognized side effects, pathological laughter has not been previously reported. Case Presentation We present the case of a 6‐year‐old boy diagnosed with both ASD and ADHD who developed sudden, uncontrollable episodes of pathological laughter after beginning low‐dose atomoxetine (5 mg/day, ~0.25 mg/kg). The child had a history of hyperactivity and aggression, managed with risperidone and clonidine. Within 5 days of initiating atomoxetine, he exhibited frequent, spontaneous laughter lasting 2–5 min without any apparent emotional trigger. These episodes resolved within 10 days despite continued atomoxetine treatment, coinciding with a minor increase in risperidone dosage. Following this period, the child displayed noticeable improvements in attention, eye contact, and overall cooperation. Atomoxetine was later increased to 10 mg/day, with no recurrence of pathological laughter.

Conclusion

This case suggests that pathological laughter may be a rare but temporary side effect of atomoxetine, even at low doses. Given the child's familial history of bipolar disorder and the influence of catecholamines on mood regulation, clinicians should be vigilant in monitoring mood‐related side effects in children with neurodevelopmental disorders. This report emphasizes the need for personalized treatment approaches and further investigation into the mechanisms and risk factors underlying this phenomenon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atomoxetine HydrochlorideAutism Spectrum DisorderAttention Deficit Disorder with HyperactivityLaughterAdrenergic Uptake InhibitorsHumansMaleChildRisperidone

Stichwörter der Autor:innen

ADHDatomoxetineautism spectrum disordermood disturbancepathological laughterpediatric neuropsychiatry

Substanzen

Atomoxetine HydrochlorideAdrenergic Uptake InhibitorsRisperidone

Autor:innen und Institutionen

  • Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Sexual and Reproductive Health Research Center, Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Psychiatry, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Aliasghar Clinical Research Development Center, Aliasghar Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Mental Health Research Center, Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Forouzan Elyasi, Arghavan Fariborzifar

Zitieren

APA

Zibaee, A., Elyasi, F., Fariborzifar, A., & Shirazi, E. (2025). Unanticipated Pathological Laughter Following Atomoxetine Administration in a Child With Autism Spectrum Disorder and Attention‐Deficit/Hyperactivity Disorder. Neuropsychopharmacology Reports, 45(3). https://doi.org/10.1002/npr2.70028

Vancouver

Zibaee A, Elyasi F, Fariborzifar A, Shirazi E. Unanticipated Pathological Laughter Following Atomoxetine Administration in a Child With Autism Spectrum Disorder and Attention‐Deficit/Hyperactivity Disorder. Neuropsychopharmacology Reports. 2025;45(3). doi:10.1002/npr2.70028

BibTeX
@article{Zibaee2025,
  author = {Zibaee, Alireza and Elyasi, Forouzan and Fariborzifar, Arghavan and Shirazi, Elham},
  title = {Unanticipated Pathological Laughter Following Atomoxetine Administration in a Child With Autism Spectrum Disorder and Attention‐Deficit/Hyperactivity Disorder},
  journal = {Neuropsychopharmacology Reports},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1002/npr2.70028}
}
Kostenlos starten →